Evidence map›Paper›PMID 33344241›Full record

ArticleFrontiers in oncology2020

Ubiquitin-Like Modifier Activating Enzyme 1 as a Novel Diagnostic and Prognostic Indicator That Correlates With Ferroptosis and the Malignant Phenotypes of Liver Cancer Cells.

Yiru Shan, Guang Yang, Haixia Huang, Yehan Zhou, Xiangyu Hu, Qiuhong Lu, Peng Guo, Jun Hou, Li Cao, Fuhua Tian and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Oncology research · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Yiru ShanDepartment of Oncology, Jiulongpo People's Hospital of Chongqing, Chongqing, China.
Guang YangDepartment of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Haixia HuangDepartment of Critical Care Medicine, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China international Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China.
Yehan ZhouDepartment of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiangyu HuDepartment of Dermatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
Qiuhong LuDepartment of Orthopaedics, Jiulongpo People's Hospital of Chongqing, Chongqing, China.
Peng GuoDepartment of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jun HouDepartment of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Li CaoDepartment of Patient Service Center, Jiulongpo People's Hospital of Chongqing, Chongqing, China.
Fuhua TianDepartment of Oncology, Jiulongpo People's Hospital of Chongqing, Chongqing, China.
Qi PanDepartment of Dermatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
Chongqing Jiulongpo People's Hospital · CNChongqing Medical University · CNSichuan Cancer Hospital · CNChongqing University of Technology · CNFirst People's Hospital of Chongqing · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFerroptosis is a type of cell death that is iron dependent, a characteristic that distinguishes it from necrosis, apoptosis, and autophagy. However, the ferroptotic mechanisms for hepatitis B virus-associated hepatocellular carcinoma (HCC) remain incompletely described.

methodsTwo hepatitis B virus-associated HCC public datasets, GSE22058 (n=192) and GSE54238 (n=23), were obtained from the NCBI Gene Expression Omnibus (GEO) database. Bioinformatics methods, including weighted gene coexpression network analysis (WGCNA), Cox regression, and LASSO analysis, were used to identify signature markers for diagnosis and prognosis. CCK8, wound healing, Transwell migration/invasion, and ferroptosis assays were employed to explore the biological function of novel candidate markers weight gene coexpression network analysis.

resultsIn total, 926 differentially expressed genes (DEGs) were common between the GSE22058 and GSE54238 datasets. Following WGCNA, 515 DEGs derived from the MEturquoise gene module were employed to establish diagnosis and prognosis models in The Cancer Genome Atlas (TCGA) HCC RNA-Seq cohort (n=423). The score of the diagnostic model was strikingly upregulated in the TCGA HCC group (

conclusionOur findings demonstrated that

Indexed as

ferroptosishepatocellular carcinomaNrf2 signal transduction pathwayUBA1weighted gene coexpression network analysis

Identifiers

PMID33344241
PMCPMC7744729
OpenAlexW3109286594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.